Prolacta Bioscience recognizes contributions of breast milk donors during National Nutrition Month
Leader in human milk nutrition
Established in 1999, Prolacta Bioscience is a privately held life sciences company that has touched the lives of more than 100,000 premature infants globally.1
Dedicated to advancing the science of human milk, we employ more than 300 people throughout the world, many of whom have dedicated their lives to neonatal care.
Together, we’re just as committed to ethical business practices, protecting the safety of our team, and fostering an inclusive culture.
Ethical practices
As we work to bring life-saving nutrition to critically ill, premature infants, we’re also committed to ethical business practices, protecting the safety of our team, and fostering an inclusive culture.
Prolacta is the world’s leading hospital provider of 100% human milk–based nutritional products.
Available to hospitals since 2006, our fortifiers changed the standard of care for extremely premature infants worldwide and are the first nutritional fortifiers made from 100% donor milk instead of cow milk.
We are also exploring the benefits of human milk including applications for infants who need surgery for congenital cardiac and gastrointestinal disorders.
Advancing the science of human milk®
As part of this commitment, we sponsor the International Conference on Human Milk Science and Innovation, a forum for the latest scientific and clinical research related to human milk. The annual conference hosts renowned scientists and neonatologists from around the world. We also work closely with clinicians and researchers to add to the growing scientific evidence on health benefits of human milk.
Press + news
See all- Press releases
- Prolacta in the news
Prolacta Bioscience neonatologist Dr. Erin Hamilton Spence earns breastfeeding and lactation medicine certification held by fewer than 100 North American physicians
FDA approves first human milk-based fortifier for term infants to support growth and recovery following surgery for Gastroschisis
Study finds fewer cases of Necrotizing Enterocolitis in premature infants and cost savings after implementing an Exclusive Human Milk Diet
Study shows vat pasteurization outperforms other methods in preserving human milk’s native bioactive properties
Hot Topics in Neonatology® 2024 Conference to feature symposium on clinical impact & cost savings of an Exclusive Human Milk Diet
Prolacta celebrates advancements in neonatal care during Prematurity Awareness Month
Humavant® 100% human milk-based fortifiers helping premature infants in Australia grow and develop
Prolacta Bioscience appoints Dr. Sandra Sullivan as director of clinical education and professional development
Prolacta Bioscience applauds passage of New York legislation expanding insurance coverage for human milk-based nutritional products
Prolacta Bioscience applauds new California state law expanding access to donor human milk for fragile infants
More than 50% of level III & IV NICUs in U.S. used Prolacta's 100% human milk-based products to help reduce Necrotizing Enterocolitis (NEC) in the smallest premature infants in 2024
Prolacta Bioscience applauds passage of the maternal health bill in Massachusetts
Working to address equity in premature nutrition, National Black Nurses Association and Prolacta Bioscience support H.R. 7141
Preterm infant study finds proactive use of Prolact CR cream improves growth and reduces NICU costs
Prolacta Bioscience demonstrates leadership in human milk science with history of voluntarily reviewing health claims with the FDA
Study shows exclusive human milk diet benefits term infants post-gastroschisis repair; Data to be presented at ESPGHAN 2024 meeting
Pediatric Academic Societies Meeting includes symposium on cost-effectiveness of implementing exclusive human milk-based nutrition for premature infants
Novel research illuminates breast milk’s unique contribution to COVID-19 defense in infants
Real-world data on human milk-based fortification reveals limitations of protocol designs of two RCTs
Prolacta's human milk-based nutrition has touched the lives of 100,000 Premature and Critically Ill Infants Globally
Prolacta Bioscience recognizes advances in preterm care during NICU awareness month
Prolacta Bioscience applauds Ohio legislature for supporting Medicaid reimbursement for donor human milk-derived products
New study shows Prolacta’s human milk-based nutritional fortifiers save hospital NICUs up to $3.4M annually
Study reveals Prolacta’s 100% human milk-based nutritional fortifiers significantly increase bioactive proteins and antioxidant activity in human milk samples, outperforming cow milk-based fortifier
Prolacta Bioscience celebrates donor moms on World Human Milk Donation Day
Prolacta Bioscience recognizes contributions of breast milk donors during National Nutrition Month
